Biotech Catalyst Calendar — April 2026

PDUFA decision date for ulixacaltamide for essential tremor

Ulixacaltamide · Essential tremor

The FDA will decide whether to approve ulixacaltamide, a first-in-class oral treatment for essential tremor — the most common movement disorder, affecting 7 million Americans. Phase 3 showed significant tremor reduction vs. placebo.

High probability of approval given strong Phase 3 data and unmet need. The real question is labeling — broad label drives blockbuster potential. Stock likely moves 20-40% on approval, 40-60% down on CRL.

Phase 3 interim analysis of povetacicept in IgA nephropathy

Povetacicept · IgA nephropathy (kidney disease)

Vertex's kidney disease drug povetacicept hits a key interim analysis. Phase 2 showed unprecedented proteinuria reduction. If Phase 3 confirms, this becomes Vertex's biggest non-CF franchise and could support accelerated approval.

Interim data should confirm proteinuria reduction in a larger population. Look for consistency with Phase 2 results showing >50% proteinuria reduction. Positive data likely triggers accelerated filing.

NTLA-2002 Phase 3 interim data in hereditary angioedema

NTLA-2002 · Hereditary angioedema (HAE)

First pivotal readout for an in vivo CRISPR gene editing therapy in HAE. Phase 1/2 showed 95% reduction in HAE attacks from a single IV infusion. Phase 3 will determine if this becomes the first in vivo CRISPR medicine ever approved.

Primary endpoint is reduction in investigator-confirmed HAE attacks. Phase 1/2 bar is 95% reduction. Any result above 80% would likely support approval. This is also a safety readout — long-term gene editing safety will be heavily scrutinized.

Voyage Phase 3 topline results for MM120 in generalized anxiety disorder

MM120 (lysergide D-tartrate) · Generalized anxiety disorder (GAD)

The first of two pivotal trials testing a psychedelic-derived medicine for anxiety. A single supervised dose of MM120 showed 12+ weeks of anxiety relief in Phase 2. This readout will determine whether psychedelic medicine for psychiatry is real or hype.

Binary event. Success (statistically significant HAM-A reduction vs placebo at 12 weeks) sends MNMD up 50-100%+. Failure sends it down 50-70%. Key risk: high placebo response rates in anxiety trials. Watch the p-value and effect size closely.

mRNA-1010 Phase 3 data for standalone flu vaccine

mRNA-1010 · Seasonal influenza

Moderna's standalone mRNA flu vaccine faces its pivotal moment. If it demonstrates superiority over traditional egg-based flu vaccines, it would validate mRNA technology beyond COVID and open a $7B+ annual market.

The key question is superiority, not just non-inferiority. If mRNA-1010 merely matches existing flu vaccines, the commercial case weakens. Look for meaningfully higher seroconversion rates and geometric mean titers, especially in elderly populations where current vaccines underperform.

Amvuttra (vutrisiran) HELIOS-B cardiovascular outcome data update

Amvuttra (vutrisiran) · ATTR cardiomyopathy

Updated cardiovascular outcomes data for Alnylam's Amvuttra in ATTR cardiomyopathy. HELIOS-B is the trial that demonstrated mortality benefit — this update provides longer follow-up. Critical for the label expansion and commercial trajectory.

Longer follow-up should confirm the mortality benefit seen in the primary analysis. Any erosion of the survival curve would concern investors. Consistent data supports a multibillion-dollar ATTR franchise.

SRP-9001 (Elevidys) confirmatory Phase 3 EMBARK study updated analysis

Elevidys (delandistrogene moxeparvovec) · Duchenne muscular dystrophy

Updated confirmatory data for Sarepta's gene therapy for Duchenne muscular dystrophy. Elevidys received accelerated approval in 2023 but needs confirmatory data to maintain its marketing authorization. Safety concerns have clouded the commercial picture.

Functional improvement on NSAA (North Star Ambulatory Assessment) vs. placebo. The earlier interim analysis was mixed. This longer-term readout is critical. If confirmatory data is weak, FDA could pull accelerated approval.

VK2735 Phase 3 VENTURE enrollment update and potential interim look

VK2735 · Obesity

Viking provides an update on enrollment progress for the pivotal VENTURE obesity trial. Fast enrollment would signal strong investigator and patient interest. An early interim look, if triggered, would provide the first Phase 3 efficacy signal.

Enrollment pace is a leading indicator. >75% enrolled would suggest topline data in early 2027. Any interim efficacy data would be a major catalyst. The stock moves on even enrollment updates in the obesity space.

BEAM-101 updated Phase 1/2 data in sickle cell disease at ASGCT

BEAM-101 · Sickle cell disease

Updated clinical data for Beam's base editing therapy for sickle cell disease, presented at the American Society of Gene & Cell Therapy meeting. Base editing is 'next-gen CRISPR' — it makes precise single-letter DNA changes without cutting both strands.

Look for fetal hemoglobin induction levels and clinical outcomes (vaso-occlusive crises). Beam needs to show their base editing approach is at least comparable to CRISPR Therapeutics' Casgevy, which sets the bar as the approved therapy.

BNT327 (PD-L1 x VEGF bispecific) Phase 2 expansion data in NSCLC

BNT327 · Non-small cell lung cancer

BioNTech presents updated data for its bispecific antibody targeting both PD-L1 and VEGF in lung cancer. This represents BioNTech's push beyond vaccines into oncology — the area that will define its post-COVID future.

Response rates and progression-free survival data in NSCLC patients. BioNTech needs to demonstrate meaningful clinical activity to justify the $15B+ it's investing in its oncology pipeline beyond vaccines.